BMS Korea, Boryung co-market Baraclude in Korea

Published: 2012-12-20 06:57:00

Updated: 2012-12-20 06:57:00

BMS Korea, a Korean branch of Bristol-Myers Squibb, and Boryung Pharm announced last Friday that the two companies have signed an agreement to co-promote Baraclude (entecavir) in Korea from next January.

Baraclude is an oral antiviral drug used in the treatment of hepatitis B infection. Baracl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK